Please ensure Javascript is enabled for purposes of website accessibility

3 Reasons BioNTech Isn't Nearly as Big as Moderna

By Keith Speights – Aug 20, 2021 at 5:55AM

Key Points

  • BioNTech's market cap is only a little over half that of Moderna's.
  • The two vaccine maker's growth projections, pipelines, and public profiles factor into the discrepancy in their valuations.

Motley Fool Issues Rare “All In” Buy Alert

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Bigger isn't always better.

Moderna (MRNA -0.23%) has delivered impressive stock gains so far in 2021. However, BioNTech (BNTX -0.88%) is by far the bigger winner year to date, with its stock skyrocketing more than 330%.  

Despite its stronger stock performance this year, BioNTech's market cap is only a little over half the size of Moderna's. Here are three reasons BioNTech isn't nearly as big as Moderna right now.

Seesaw with two money bags on each end.

Image source: Getty Images.

1. Lower expected sales

It makes sense that a company with significantly lower revenue and earnings would have a lower market cap than a rival with stronger financial results. But BioNTech actually outperformed Moderna on both fronts in the companies' latest quarterly updates.

In the second quarter, BioNTech reported revenue of 5.3 billion euros (around $6.2 billion). The German biotech posted earnings of nearly 2.8 billion euros (close to $3.3 billion). By comparison, Moderna's Q2 revenue totaled $4.4 billion, and it generated earnings of $2.8 billion.

So why does BioNTech have a lower valuation than Moderna? One main reason is that the company projects lower sales for full-year 2021. BioNTech expects full-year sales of 15.9 billion euros (roughly $18.6 billion). Moderna looks for full-year revenue of $20 billion. BioNTech and Pfizer split the profits on the sales of their COVID-19 vaccine. Moderna, however, pockets all of the revenue from its vaccine. 

Neither BioNTech nor Moderna has provided guidance for 2022 yet. However, Moderna revealed that it has already secured advanced purchase agreements totaling around $12 billion for next year with options worth another $8 billion. 

2. Less advanced pipeline

The differences between BioNTech's and Moderna's financial results don't fully explain the discrepancy in the valuations of the two vaccine stocks. There's another factor likely at play, though.

Investors are always looking to the future. For biotechs like BioNTech and Moderna, that means their pipelines are important to their valuations. And investors probably are more excited about Moderna's pipeline. 

BioNTech doesn't currently have any late-stage candidate other than its COVID-19 vaccine. Moderna plans to advance its mRNA-1647 cytomegalovirus (CMV) vaccine into late-stage testing this year. The company thinks the CMV vaccine could generate sales of between $2 billion and $5 billion if it goes on to win regulatory approvals. 

Moderna also has a much larger cash stockpile to use in bolstering its pipeline than BioNTech does. As of June 30, 2021, Moderna's cash, cash equivalents, and investments totaled $12.2 billion. BioNTech's cash position stood at 914.1 million euros (nearly $1.1 billion) at the end of the second quarter.

3. Lower profile

There's another reason why BioNTech is so much smaller than Moderna that could be more important than you might think. BioNTech has a much lower public profile than Moderna does.

Part of the challenge for BioNTech on this front is that it's overshadowed (especially in the U.S.) by its big partner, Pfizer. Many people refer only to the Pfizer and Moderna vaccines, leaving BioNTech out altogether.

I wouldn't go as far as to call BioNTech the Rodney Dangerfield of biotech stocks. Unlike the late comedian, BioNTech does get respect from investors. Its sizzling stock performance this year proves the point. However, BioNTech hasn't received nearly as much hype as Moderna has. 

Bigger isn't always better

For right or wrong, these three reasons go a long way toward explaining why BioNTech isn't nearly as big as Moderna. But bigger isn't always better.

There are major questions about how sustainable Moderna's sky-high market cap actually is. One prominent analyst predicts that the stock will plunge close to 70% because its present valuation isn't warranted. 

Granted, quite a few Wall Street analysts think that BioNTech is overpriced at current levels, as well. However, there's an old saying: "The bigger they are, the harder they fall." BioNTech's smaller size in comparison to Moderna just might be an advantage in the not-too-distant future.

Keith Speights owns shares of Pfizer. The Motley Fool recommends Moderna Inc. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

BioNTech SE Stock Quote
BioNTech SE
BNTX
$154.85 (-0.88%) $-1.38
Pfizer Stock Quote
Pfizer
PFE
$49.21 (0.74%) $0.36
Moderna Inc. Stock Quote
Moderna Inc.
MRNA
$176.40 (-0.23%) $0.41

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
356%
 
S&P 500 Returns
118%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/26/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.